Načítá se...
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) claims almost 80% of the total lung cancer cases, with the late-stage disease having an estimated median survival time of up to five years. Patients with NSCLC benefit from traditional maximum tolerated dose (MTD) chemotherapy alone or combined with...
Uloženo v:
| Vydáno v: | Cancers (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8071233/ https://ncbi.nlm.nih.gov/pubmed/33920884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081901 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|